H.C. Wainwright assumed coverage of Aligos Therapeutics (ALGS) with a Buy rating and $50 price target The firm has conviction that ALG-000184 can become the new standard-of-care for chronic suppression of hepatitis B virus, while also serving as the oral backbone to future functional cure regimens.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
- Aligos Therapeutics Reports Q2 2025 Progress and Results
- Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)
- Aligos Therapeutics Approves Major Amendments at Annual Meeting